CannaPharmaRX Statistics
Total Valuation
CannaPharmaRX has a market cap or net worth of 2.55 million. The enterprise value is 23.83 million.
| Market Cap | 2.55M |
| Enterprise Value | 23.83M |
Important Dates
The last earnings date was Friday, April 10, 2026.
| Earnings Date | Apr 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CannaPharmaRX has 672.27 million shares outstanding. The number of shares has increased by 5.95% in one year.
| Current Share Class | 672.27M |
| Shares Outstanding | 672.27M |
| Shares Change (YoY) | +5.95% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.72% |
| Owned by Institutions (%) | n/a |
| Float | 623.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.88 |
| PB Ratio | -0.08 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.14 |
| EV / Sales | 17.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -29.99 |
Financial Position
The company has a current ratio of 0.04
| Current Ratio | 0.04 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -25.99 |
| Interest Coverage | -1.37 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -23.44% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 13.62% |
| Weighted Average Cost of Capital (WACC) | -969.26% |
| Revenue Per Employee | 52,391 |
| Profits Per Employee | -428,133 |
| Employee Count | 26 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 3.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.91% in the last 52 weeks. The beta is -1,615.32, so CannaPharmaRX's price volatility has been lower than the market average.
| Beta (5Y) | -1,615.32 |
| 52-Week Price Change | -30.91% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 45.59 |
| Average Volume (20 Days) | 148,967 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, CannaPharmaRX had revenue of 1.36 million and -11.13 million in losses. Loss per share was -0.02.
| Revenue | 1.36M |
| Gross Profit | -2.39M |
| Operating Income | -3.35M |
| Pretax Income | -11.13M |
| Net Income | -11.13M |
| EBITDA | n/a |
| EBIT | -3.35M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 1,804 in cash and 20.65 million in debt, with a net cash position of -20.65 million or -0.03 per share.
| Cash & Cash Equivalents | 1,804 |
| Total Debt | 20.65M |
| Net Cash | -20.65M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | -30.15M |
| Book Value Per Share | -0.05 |
| Working Capital | -30.28M |
Cash Flow
In the last 12 months, operating cash flow was -789,102 and capital expenditures -5,519, giving a free cash flow of -794,621.
| Operating Cash Flow | -789,102 |
| Capital Expenditures | -5,519 |
| Depreciation & Amortization | n/a |
| Net Borrowing | 794,269 |
| Free Cash Flow | -794,621 |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | -175.34% |
| Operating Margin | -245.77% |
| Pretax Margin | -817.19% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | -245.77% |
| FCF Margin | n/a |
Dividends & Yields
CannaPharmaRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.95% |
| Shareholder Yield | -5.95% |
| Earnings Yield | -435.74% |
| FCF Yield | -31.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CannaPharmaRX has an Altman Z-Score of -28.91 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -28.91 |
| Piotroski F-Score | 4 |